secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001213900-25-048507
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex Healthcare advances IHL-42X RePOSA trial to Phase 3 after FDA clearance
--------------------------------------------------------------------------------

- FDA cleared Phase 3 protocol for IHL-42X under IND; trial for obstructive sleep apnea (OSA) with no approved oral therapy.
- Phase 3 will be US-only, leveraging Phase 2 infrastructure; ~20 existing sites roll over, 10 new sites added.
- Study design: randomized, placebo-controlled, 12 months, including head-to-head against monotherapy components.
- Primary endpoint: change in Apnea-Hypopnea Index (AHI); top-line Phase 2 results due in coming weeks.
- CEO cites potential to become first FDA-approved oral therapy for OSA; commercial discussions underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025048507/0001213900-25-048507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025048507/ea0243466-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-048507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer